Phase 2 Meningioma Clinical Trials
19 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–19 of 19 trials
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Intracranial Meningioma
RTOG Foundation, Inc.153 enrolled11 locationsNCT06955169
Recruiting
Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Grade 2 MeningiomaRecurrent MeningiomaGrade 1 Meningioma+2 more
Mayo Clinic42 enrolled1 locationNCT04082520
Recruiting
Phase 1Phase 2
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled781 locationsNCT02523014
Recruiting
Phase 2
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Meningioma, Malignant
Istituto Oncologico Veneto IRCCS104 enrolled17 locationsNCT06275919
Recruiting
Phase 2
Abemaciclib in Newly Diagnosed Meningioma Patients
Meningioma
Nader Sanai72 enrolled1 locationNCT05940493
Recruiting
Phase 2
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Meningioma
Baptist Health South Florida24 enrolled3 locationsNCT05425004
Recruiting
Phase 2
NEO100 and High-Grade Meningioma
Residual, Progressive or Recurrent Grade II or III Meningioma
Neonc Technologies, Inc.30 enrolled3 locationsNCT05023018
Recruiting
Phase 1Phase 2
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Recurrent Meningioma
Joshua Palmer30 enrolled1 locationNCT07150806
Recruiting
Phase 2
177Lu-DOTATATE for Recurrent Meningioma
Recurrent Meningioma
European Organisation for Research and Treatment of Cancer - EORTC136 enrolled12 locationsNCT06326190
Recruiting
Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Grade II MeningiomaGrade III MeningiomaAtypical Meningioma+3 more
Northwestern University27 enrolled8 locationsNCT02847559
Recruiting
Phase 2
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
Grade I Meningioma, AdultGrade II Meningioma, AdultGrade III Meningioma, Adult+1 more
Nancy Ann Oberheim Bush, MD37 enrolled1 locationNCT04659811
Recruiting
Phase 1Phase 2
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Meningioma
University Hospital, Basel, Switzerland18 enrolled1 locationNCT04997317
Recruiting
Phase 2
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
Meningioma
Central Hospital, Nancy, France28 enrolled2 locationsNCT06126588
Recruiting
Phase 2
Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema
GlioblastomaMeningiomaCerebral Metastases
Peter Siesjö20 enrolled1 locationNCT06710249
Recruiting
Phase 2
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
MeningiomaGliomaLow-grade Glioma
Rigshospitalet, Denmark40 enrolled1 locationNCT06684795
Recruiting
Phase 1Phase 2
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Brain MetastasesBrain TumorBrain Cancer+4 more
Essen Biotech85 enrolled1 locationNCT06640582
Terminated
Phase 2
Peptide Receptor Radionuclide Therapy administered to Participants with Meningioma with 67Cu-SARTATE™
Meningioma
Clarity Pharmaceuticals Ltd.6 enrolled1 locationACTRN12618000309280